A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis

Inclusion Criteria: * Histologically-proven squamous cell carcinoma of the penis * Performance status ECOG 0-2 * Written informed consent * Measurable disease as per RECIST 1.1 * Fit to receive cabazitaxel as second line chemotherapy * Previously received TPF or cisplatin-5FU as first line systemic chemotherapy for penile cancer * Adequate organ function as evidenced by the following peripheral blood counts and serum biochemistry at enrollment: * Neutrophils ≥1.5 x 109/L * Haemoglobin ≥10 g/dL * Platelets ≥100 x 109/L * Total bilirubin \<1.5 upper limit of normal (ULN) * Alanine aminotransferase/serum glutamate pyruvate transaminase (ALT/SGPT) ≤1.5 x ULN * Serum creatinine ≤1.5 x ULN. (If creatinine is 1.0-1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with a creatinine clearance \<60 ml/min should be excluded.) Exclusion Criteria: * Pure veruccous carcinoma of the penis * Squamous carcinoma of the urethra * T1 N1 M0 disease * T2 N1 M0 disease * Unfit for this regimen (as assessed by the multidisciplinary team) * Contraindication to chemotherapy * ECOG Performance Status \> 2 * Active Grade ≥2 peripheral neuropathy * Active secondary cancers * Other concurrent serious illness or medical conditions * Electrocardiogram (ECG) evidence of uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension, history of congestive heart failure, or myocardial infarction within last 6 months. * Uncontrolled diabetes mellitus. * History of severe hypersensitivity reaction (≥grade 3) to docetaxel * History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs * Active infection requiring systemic antibiotic or anti-fungal medication * Participation in another clinical trial with any investigational drug within 30 days prior to study registration. * Concurrent or planned treatment with strong inhibitors of cytochrome P450 3A4/5. A 1-week washout period is necessary for patients who are already on these treatments. * Concurrent or planned treatment with strong inducers of cytochrome P450 3A4/5. A 1-week washout period is necessary for patients who are already on these treatments.